ADDEX N/ CH0029850754 /
2024-11-15 5:31:42 PM | Chg. -0.0058 | Volume | Bid5:40:00 PM | Ask5:40:00 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
0.0590CHF | -8.95% | 1.41 mill. Turnover: 87,025.8696 |
0.0590Bid Size: 237,788 | 0.0626Ask Size: 6,413 | 10.52 mill.CHF | - | - |
GlobeNewswire
08-27
Addex and Indivior Select Clinical Candidates from GABAB Positive Allosteric Modulator Research Coll...
GlobeNewswire
07-15
Addex Presents Positive Results from GABAB PAM Cough Program at the Thirteenth London International ...
GlobeNewswire
07-12
Addex To Present at the Thirteenth London International Cough Symposium (13th LICS)
GlobeNewswire
06-06
Addex Therapeutics Reports Q1 2024 Financial Results and Provides Corporate Update
GlobeNewswire
05-31
Addex Therapeutics to Release Q1 2024 Financial Results and Host Conference Call on June 6, 2024
GlobeNewswire
04-18
Addex Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update
GlobeNewswire
04-11
Addex Therapeutics to Release Full-Year 2023 Financial Results and Host Conference Call on April 18,...
GlobeNewswire
04-03
Addex and Perceptive Launch Neurosterix with $63 Million to Accelerate Development of Allosteric Mod...
GlobeNewswire
01-31
Addex Enters into At-The-Market ADS Offering Agreement with H.C. Wainwright & Co. LLC.